- PR Newswire•28 days ago
Michael Macaluso, Ampio's CEO, noted "We are grateful to the FDA for the number of fair and reasonable paths forward to a Biological License for Ampion™ they have provided to Ampio. Macaluso noted "The AP-011 hand trial was a small pilot study designed to examine the safety of a single injection of Ampion™ into the basal thumb joint of patients with hand OA, which is common, troublesome, and has limited treatment options. Safety was examined by reported adverse events (AEs) during the study period and reduction of pain was assessed with the AUSCAN A index (5 questions related to pain and validated for OA of the hand).
- PR Newswire•2 months agoAmpio Announces Accepted Publication of the Clinical Trial Results of Its Oral Drug, Optina™, Treatment of Diabetic Macular Edema
ENGLEWOOD, Colo., Oct. 4, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that a manuscript titled: "Potential Beneficial Effect of Low Dose Danazol in Combination With Renin Angiotensin Inhibitors in Diabetic Macular Edema" was accepted for publication in Acta Ophthalmologica, an international peer-reviewed journal in the field of ophthalmology. Ampio's CSO, Dr. David Bar-Or, explained "The article, coauthored by Dr. Michael Singer, retinologist at the University of Texas, reports the clinical benefits of Optina™, from a 12-week multi-center, placebo-controlled, double-masked randomized trial which identified a reversal of pathological changes and a synergistic effect with other medication. Dr. Singer, who previously presented the results of this trial at the World Congress of Ophthalmology and at The Association for Research in Vision and Ophthalmology (ARVO), also presented these findings recently at the 2016 annual meeting of the Retina Society held in San Diego, CA.
- PR Newswire•2 months ago
ENGLEWOOD, Colo., Sept. 29, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced the Company has met with the CBER Division of the FDA to seek guidance on the best path forward to obtain a Biological License for Ampion™ to treat patients suffering from pain caused by severe osteoarthritis of the knee (OAK). Michael Macaluso, Ampio's CEO noted, "We are grateful to CBER for their thorough review of our data, which referenced over 1800 patients across multiple trials. CBER's guidance included a number of very good options and as a result, we are continuing discussions.
AMPE : Summary for Ampio Pharmaceuticals, Inc. - Yahoo Finance
Ampio Pharmaceuticals, Inc. (AMPE)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Bid||0.96 x 2200|
|Ask||0.97 x 1700|
|Day's Range||0.91 - 0.99|
|52 Week Range||0.59 - 4.32|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-1.97|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|